The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Bone Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bone Diseases


Psychiatry related information on Bone Diseases


High impact information on Bone Diseases


Chemical compound and disease context of Bone Diseases


Biological context of Bone Diseases


Anatomical context of Bone Diseases


Gene context of Bone Diseases

  • Thus, abnormal STAT activation and p21(WAF1/CIP1) expression by the TDII mutant receptor may be responsible for this FGFR3-related bone disease [28].
  • Our study places the IFN-beta system in a new context, and may offer a molecular basis for the treatment of bone diseases [29].
  • Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [30].
  • Furthermore, HGF emerges as a possible factor involved in myeloma bone disease by its ability to induce IL-11 [24].
  • SUMMARY: Identification of pathogenic mutations and allelic variations in LRP5 has improved our understanding of the physiology of bone mass acquisition and the pathophysiology of several bone diseases, including osteoporosis [31].

Analytical, diagnostic and therapeutic context of Bone Diseases


  1. Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. Kyle, R.A., Jowsey, J., Kelly, P.J., Taves, D.R. N. Engl. J. Med. (1975) [Pubmed]
  2. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Frattini, A., Orchard, P.J., Sobacchi, C., Giliani, S., Abinun, M., Mattsson, J.P., Keeling, D.J., Andersson, A.K., Wallbrandt, P., Zecca, L., Notarangelo, L.D., Vezzoni, P., Villa, A. Nat. Genet. (2000) [Pubmed]
  3. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Hughes, D.E., Dai, A., Tiffee, J.C., Li, H.H., Mundy, G.R., Boyce, B.F. Nat. Med. (1996) [Pubmed]
  4. Accelerated progression of chronic renal insufficiency after parathyroidectomy. Collier, V.U., Mitch, W.E. JAMA (1980) [Pubmed]
  5. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. Harrell, R.M., Lyles, K.W., Harrelson, J.M., Friedman, N.E., Drezner, M.K. J. Clin. Invest. (1985) [Pubmed]
  6. Metabolic abnormalities in HIV disease and injection drug use. Dobs, A., Brown, T. J. Acquir. Immune Defic. Syndr. (2002) [Pubmed]
  7. Sonophoresis-mechanisms and application. Vranić, E. Bosnian journal of basic medical sciences / Udruženje basičnih mediciniskih znanosti = Association of Basic Medical Sciences. (2004) [Pubmed]
  8. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. Candeliere, G.A., Glorieux, F.H., Prud'homme, J., St-Arnaud, R. N. Engl. J. Med. (1995) [Pubmed]
  9. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky, I.B., Foley, J., Nelson, P., Goodman, W.G. N. Engl. J. Med. (1991) [Pubmed]
  10. Parathyroid hormone in aluminum bone disease. Duarte, R. N. Engl. J. Med. (1985) [Pubmed]
  11. Use of dichloromethylene diphosphonate in metastatic bone disease. Jung, A., Chantraine, A., Donath, A., van Ouwenaller, C., Turnill, D., Mermillod, B., Kitler, M.E. N. Engl. J. Med. (1983) [Pubmed]
  12. Pharmacokinetics of pamidronate in patients with bone metastases. Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J.M., Burckhardt, P. J. Natl. Cancer Inst. (1992) [Pubmed]
  13. Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure. Malluche, H.H., Faugere, M.C., Friedler, R.M., Matthews, C., Fanti, P. J. Clin. Invest. (1987) [Pubmed]
  14. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins. Duncan, G., McCormick, C., Tufaro, F. J. Clin. Invest. (2001) [Pubmed]
  15. Aluminium-related bone disease and haemodialysis. Seyfert, U.T., Didion, K., Albert, F.W. Lancet (1987) [Pubmed]
  16. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). van Breukelen, F.J., Bijvoet, O.L., van Oosterom, A.T. Lancet (1979) [Pubmed]
  17. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Edwards, C.M., Edwards, J.R., Lwin, S.T., Esparza, J., Oyajobi, B.O., McCluskey, B., Munoz, S., Grubbs, B., Mundy, G.R. Blood (2008) [Pubmed]
  18. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, E.F., Mak, T.W., Serfling, E., Takayanagi, H. J. Exp. Med. (2005) [Pubmed]
  19. Transduction of cell survival signals by connexin-43 hemichannels. Plotkin, L.I., Manolagas, S.C., Bellido, T. J. Biol. Chem. (2002) [Pubmed]
  20. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. Eriksen, E.F., Charles, P., Melsen, F., Mosekilde, L., Risteli, L., Risteli, J. J. Bone Miner. Res. (1993) [Pubmed]
  21. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. Hoyland, J.A., Freemont, A.J., Sharpe, P.T. J. Bone Miner. Res. (1994) [Pubmed]
  22. The cDNA cloning of the transcripts of human PEBP2alphaA/CBFA1 mapped to 6p12.3-p21.1, the locus for cleidocranial dysplasia. Zhang, Y.W., Bae, S.C., Takahashi, E., Ito, Y. Oncogene (1997) [Pubmed]
  23. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Tondravi, M.M., McKercher, S.R., Anderson, K., Erdmann, J.M., Quiroz, M., Maki, R., Teitelbaum, S.L. Nature (1997) [Pubmed]
  24. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Hjertner, O., Torgersen, M.L., Seidel, C., Hjorth-Hansen, H., Waage, A., Børset, M., Sundan, A. Blood (1999) [Pubmed]
  25. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M., Rahemtulla, A. Blood (2003) [Pubmed]
  26. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Giuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., Bataille, R., Rizzoli, V. Blood (2002) [Pubmed]
  27. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. Graves, L., Stechschulte, D.J., Morris, D.C., Lukert, B.P. J. Bone Miner. Res. (1990) [Pubmed]
  28. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Su, W.C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W.A., Fu, X.Y. Nature (1997) [Pubmed]
  29. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., Wagner, E.F., Taniguchi, T. Nature (2002) [Pubmed]
  30. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Croucher, P.I., Shipman, C.M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Brabbs, A.C., van Beek, E.J., Holen, I., Skerry, T.M., Dunstan, C.R., Russell, G.R., Van Camp, B., Vanderkerken, K. Blood (2001) [Pubmed]
  31. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Ferrari, S.L., Deutsch, S., Antonarakis, S.E. Curr. Opin. Lipidol. (2005) [Pubmed]
  32. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. Price, P.A., Parthemore, J.G., Deftos, L.J. J. Clin. Invest. (1980) [Pubmed]
  33. Persistent severe hypercalcemia during maintenance hemodialysis. Johnson, W.J. Ann. Intern. Med. (1980) [Pubmed]
  34. Reduced serum levels of 1 alpha,25-dihydroxyvitamin D during long-term total parenteral nutrition. Klein, G.L., Horst, R.L., Norman, A.W., Ament, M.E., Slatopolsky, E., Coburn, J.W. Ann. Intern. Med. (1981) [Pubmed]
  35. RANK ligand and osteoprotegerin in myeloma bone disease. Sezer, O., Heider, U., Zavrski, I., Kühne, C.A., Hofbauer, L.C. Blood (2003) [Pubmed]
  36. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Hjertner, O., Hjorth-Hansen, H., Börset, M., Seidel, C., Waage, A., Sundan, A. Blood (2001) [Pubmed]
WikiGenes - Universities